Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
- 591 Downloads
Background Polypharmacy—taking five or medications per day—is common in lung cancer patients. This patient group is prescribed medication to control acute symptoms associated with cancer and also to prevent or treat other long-term conditions. These medications increase the pill burden for the patient and also the probability of developing a drug-related toxicity. Objective To assess the prevalence of inappropriate medication in patients taking erlotinib for the treatment of advanced non-small cell lung cancer. Method This was a multicentre study across three sites in the North of England. Medication histories for patients receiving erlotinib were retrospectively extracted from medical notes and assessed by the clinical team (a consultant pharmacist, nurse specialist and clinical oncologist) to determine if the medication was appropriate or inappropriate. The clinical team considered the following factors when deciding if the medication was appropriate or inappropriate: remaining life expectancy of the patient, time until benefit of the treatment, goals of care and treatment targets. Results Among the 20 patients assessed, 19 (95 %) according to the clinical team were taking medications that were inappropriate. The mean number of medications the patients were taking was 8 (range 1–16) and the most common class of medication used were drugs affecting the Central Nervous System. In addition, there were 11 patients (55 %) who were taking erlotinib in combination with a proton pump inhibitor (PPI)—a clinically significant drug interaction that impairs the absorption of erlotinib. Conclusions Patients taking erlotinib for the treatment of advanced non-small cell lung cancer take many inappropriate medications for the treatment or prevention of long-term conditions. These patients should have their medications reviewed in the context of their original therapeutic goals.
KeywordsErlotinib Inappropriate medication Limited life expectancy Lung cancer Medication review Polypharmacy
Conflicts of interest
None of the authors have any conflicts of interest concerning this work.
- 11.Tarceva Summary of Product Characteristics. Available at http://www.medicines.org.uk/EMC/medicine/16781/SPC/Tarceva+25mg%2c+100mg+and+150mg+Film-Coated+Tablets/. Accessed 21 Nov 2012.
- 12.Conlon LS, Romero-Ortuno R, Smyth B, Ryan R, Cogan L. General and risk management, patient safety (including: medication errors, quality control): the effect of pharmacist intervention on psychotropic prescribing through clinical medication review in a long-term care hospital in Dublin. Eur J Hosp Pharm. 2012;19:127–8.Google Scholar
- 16.Hilton JF, Seymour J, Le Maitre A, Tu D, Shepherd FA and Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. J Clin Oncol. 2011;29(suppl) (abstr 7523).Google Scholar